# Ambrisentan for Treatment of Portopulmonary Hypertension

> **NCT01733095** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Medical University of Graz**

## Conditions studied

- Portopulmonary Hypertension

## Interventions

- **DRUG:** ambrisentan

## Key facts

- **NCT ID:** NCT01733095
- **Lead sponsor:** Medical University of Graz
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-07
- **Primary completion:** 2016-04
- **Final completion:** 2016-06
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** slow recruitment
- **Last updated:** 2016-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01733095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01733095, "Ambrisentan for Treatment of Portopulmonary Hypertension". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT01733095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*